Lu-177-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update
NUCLEAR MEDICINE COMMUNICATIONS, cilt.39, sa.8, ss.789-796, 2018 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 39 Sayı: 8
- Basım Tarihi: 2018
- Doi Numarası: 10.1097/mnm.0000000000000874
- Dergi Adı: NUCLEAR MEDICINE COMMUNICATIONS
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.789-796
- Anahtar Kelimeler: Lu-177-DOTATATE, neuroendocrine tumours, octreotide, peptide receptor radionuclide therapy, radionuclide therapy, somatostatin, RECEPTOR RADIONUCLIDE THERAPY, PHASE-II, MIDGUT, NEOPLASMS, CARCINOMAS, OCTREOTIDE, EXPRESSION, TOXICITY, EFFICACY, TRIAL
- İstanbul Üniversitesi Adresli: Evet
Özet
Purpose Upon diagnosis, distant metastases are encountered in 21-50% of neuroendocrine tumours (NETs). However, few systemic treatment options are available for the well-differentiated NETs in the metastatic stage. Lu-177-DOTATATE is one of the most effective treatments in this limited patient group. We retrospectively investigated its efficacy and effect on the survival in patients with both well-differentiated and grade III NETs who had high uptake in pretherapeutic Ga-68-DOTATATE PET/computed tomography scans.